Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study.
biomarker
hyaluronan
hyaluronic acid
predictive
prognostic
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
02 Nov 2022
02 Nov 2022
Historique:
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
10
11
2022
Statut:
epublish
Résumé
Hyaluronan (HA) accumulation is associated with tumorigenesis and aggressive tumor behavior. We investigated the biomarker potential of HA in non-small cell lung cancer (NSCLC). HA levels were scored using affinity histochemistry in 137 NSCLC samples stratified by HA score ≤10, 11-20, 21-30, and >30 with HA-high defined as ≥25% expression in the extracellular matrix (ECM) of the tumor surface area. Overall survival (OS) and time to progression from initiation of taxane therapy (TTP) were compared using log-rank tests based on HA score. Of 122 patients with recurrent/metastatic NSCLC, 93 had mean HA scores that were not significantly different across clinicopathologic variables. Frequency of HA-high tumors did not differ by histology (34/68 adenocarcinomas vs. 12/25 squamous tumors, Fisher's In this NSCLC cohort, tumor HA level represents a potential biomarker for TTP, which remains a cornerstone of NSCLC therapy. Further validation is warranted to identify the HA accumulation threshold associated with clinical benefit.
Identifiants
pubmed: 36342462
pii: 28304
doi: 10.18632/oncotarget.28304
pmc: PMC9629814
doi:
Substances chimiques
Hyaluronic Acid
9004-61-9
Biomarkers
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1202-1214Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
J Thorac Cardiovasc Surg. 1999 Jan;117(1):32-6; discussion 37-8
pubmed: 9869756
Clin Epidemiol. 2011;3:139-48
pubmed: 21607015
Gen Thorac Cardiovasc Surg. 2015 Sep;63(9):507-13
pubmed: 26022944
Biomol Ther (Seoul). 2017 Jul 1;25(4):411-416
pubmed: 28208014
Braz J Med Biol Res. 2015 Nov;48(11):1039-47
pubmed: 26352698
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1822-5
pubmed: 25973074
Lung Cancer. 2013 Dec;82(3):491-8
pubmed: 24161718
J Thorac Cardiovasc Surg. 2003 Aug;126(2):558-62
pubmed: 12928658
Exp Cell Res. 2011 Feb 15;317(4):383-91
pubmed: 21134368
Adv Cancer Res. 2014;123:35-65
pubmed: 25081525
Jpn J Clin Oncol. 2012 Mar;42(3):189-95
pubmed: 22210923
Cancer Res. 1998 Jan 15;58(2):342-7
pubmed: 9443415
Tumour Biol. 2014 Aug;35(8):7383-9
pubmed: 24913707
Oncotarget. 2016 Jun 28;7(26):39957-39969
pubmed: 27220886
J Biomed Nanotechnol. 2013 Feb;9(2):299-302
pubmed: 23627059
Genes Dev. 2016 Dec 1;30(23):2623-2636
pubmed: 28007785
Virchows Arch. 1999 Jan;434(1):37-44
pubmed: 10071233
Braz J Med Biol Res. 2015 Jun;48(6):557-67
pubmed: 25992645
J Clin Oncol. 2018 Feb 1;36(4):359-366
pubmed: 29232172
Am J Pathol. 2000 Feb;156(2):529-36
pubmed: 10666382
Cancer Lett. 2006 Nov 8;243(1):71-9
pubmed: 16406327
J Biomed Biotechnol. 2010;2010:485468
pubmed: 20671927
J Thorac Oncol. 2008 Jan;3(1):46-52
pubmed: 18166840
Cancer Res. 2000 Jan 1;60(1):150-5
pubmed: 10646867
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Int J Cancer. 2001 Jan 20;95(1):12-7
pubmed: 11241304
Front Immunol. 2015 Apr 14;6:169
pubmed: 25926834
Int J Clin Exp Pathol. 2014 Jun 15;7(7):3632-46
pubmed: 25120740